Home » News » PLC News » Oncimmune Holdings paper highlights potential of ImmunoINSIGHTS in the early diagnosis of Rheumatoid arthritis
Rheumatoid arthritis

Oncimmune Holdings paper highlights potential of ImmunoINSIGHTS in the early diagnosis of Rheumatoid arthritis

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted the publication of research, supported by its ImmunoINSIGHTS team, in Arthritis Research & Therapy1, entitled ‘Profiling IgG antibodies targeting unmodified and corresponding citrullinated autoantigens in a multicentre national cohort of early arthritis in Germany’. The published paper demonstrates the potential to improve early Rheumatoid arthritis (RA) detection using autoantibodies, which, when combined with appropriate therapy/treatment could substantially improve outcomes for patients.

ImmunoINSIGHTS, Oncimmune’s autoantibody profiling technology and service business, continues to work in partnership with therapy developers to generate, actionable, value-adding insights for their drug development programmes.

Rheumatoid arthritis is characterised by an inflammation with subsequent progressive destruction of joints. Approximately one-third of people stop work because of RA within 2 years of its onset, increasing thereafter. However, the currently widely available tests for rheumatoid factor and anti-citrullinated peptide antibodies (ACPA) can only be detected in 70-80% of RA patients, and hence the disease is commonly under-diagnosed.

The aim of the research, led by Oncimmune’s Dr. Petra Buddle and Dr Hans-Dieter Zucht, was to assess the diagnostic potential of IgG antibodies to citrullinated and corresponding native autoantigens in early arthritis. The multicentre study involved a total of 411 patients, enrolled at baseline, and a serum sample drawn for autoantibody profiling. 309 (75.2%) patients were eventually classified as having RA. For further analysis, the cohort was randomly split into a test cohort (n = 329) and a validation cohort (n = 82). Patients eventually classified as having RA during follow-up were compared to patients who were not classified as having RA during follow-up.

The paper concludes that the autoantibody, cTRA2B-IgG, has the potential to improve diagnosis of early stage rheumatoid arthritis, which to date has been challenging due to current availability of diagnostics in the therapeutic area.

Dr Adam M Hill, CEO of Oncimmune Holdings said: “Oncimmune’s ImmunoINSIGHTS team have once again contributed world class science to our collective understanding of a disabling disease, moving the needle in a hard to treat condition. RA is insidious in onset, often resulting in a diagnosis later in the evolution of the disease; clearly, candidate biomarkers able to identify the disease earlier in the majority of sufferers presents a near term opportunity to dramatically improve outcomes. Whilst we remain steadfast in our commitment to cancer patients – supporting the clinical understanding of autoimmune disease biomarkers better enables us to predict side effects in cancer patients treated with immune modulating drugs – the potential to work with biopharma in autoimmune disease is also a possibility”. 

Join us on our new LinkedIn page

Follow us on LinkedIn